Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice - Takeaways - MDSpire

Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice

  • By

  • Claire Victoria Ong

  • Wolfram Samlowski

  • February 11, 2025

  • 0 min

Share

  • 1

    Brain metastases occur in nearly 75% of metastatic melanoma patients, significantly impacting their prognosis and overall survival.

  • 2

    Ipilimumab plus nivolumab therapy has improved outcomes for metastatic melanoma, achieving a melanoma-specific survival of 52%.

  • 3

    In a study of 73 patients, 27.4% developed brain metastases, with 19.2% having them at initial diagnosis.

  • 4

    The most common mutation in patients with brain metastases was BRAF V600E, found in 60% of those affected.

  • 5

    Delayed onset of brain metastases occurred in only 11.2% of patients after starting ipilimumab plus nivolumab treatment.

Original Source(s)

Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice

  • by Claire Victoria Ong, Wolfram Samlowski

  • February 11, 2025

Related Content

Severe immune-related autoimmune hemolytic anemia induced by pembrolizumab: a case report with novel immunosuppressive strategy

A model combining deep learning and ensemble learning for melanoma recognition via dermoscopy

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward

  • May 26, 2026

  • 9 min